000			02188cam a2200337 a 4500
003			EG-GiCUC
005			20250223031101.0
008			141029s2014 ua dh f m 000 0 eng d
040			_aEG-GiCUC _beng _cEG-GiCUC
041	0		_aeng
049			_aDeposite
097			_aM.Sc
099			_aCai01.08.08.M.Sc.2014.Ma.F
100	0		_aMary Yosry Aziz Faragallah
245	1	0	_aFormulation and evaluation of controlled release parenteral in situ forming drug delivery system / _cMary Yosry Aziz Faragallah ; Supervised Soad A. Yehia , Sally A. Abdelhalim
246	1	5	_aص{u٠٦أأ}اغة و تق{u٠٦أأ}{u٠٦أأ}م أنظمة توص{u٠٦أأ}ل منضبطة الانطلاق متكونة فى الموضع عن طر{u٠٦أأ}ق الحقن
260			_aCairo : _bMary Yosry Aziz Faragallah , _c2014
300			_a175 P. : _bcharts , facsimiles ; _c25cm
502			_aThesis (M.Sc.) - Cairo University - Faculty of Pharmacy - Department of Pharmaceutics
520			_aThe aim of this thesis is to formulate controlled release in situ forming implants (ISI) and in situ forming microparticles (ISM) containing lornoxicam for management of postoperative and arthritic pain in order to decrease dosing frequency and increase patient compliance. Polymeric in situ implant solutions were prepared using different concentrations of Poly - DL - lactide (PDL) or DL - lactide/glycolide copolymer (PDLG) solutions with different inherent viscosities in N{u2013} methyl pyrrolidone (NMP) using 2² X 4 factorial experimental design, where sixteen formulae were prepared. Non polymeric in situ implant solutions prepared using different concentrations of lipids like cetyl alcohol and stearyl alcohol and also sucrose acetate isobutyrate (SAIB) using 3² factorial experimental design, resulting in nine formulae
530			_aIssued also as CD
653		4	_aIn situ forming implant
653		4	_ain situ forming microparticles
653		4	_aLornoxicam
700	0		_aSally Adel Abdelhalim , _eSupervisor
700	0		_aSoad Aly Yehia , _eSupervisor
856			_uhttp://172.23.153.220/th.pdf
905			_aNazla _eRevisor
905			_aSamia _eCataloger
942			_2ddc _cTH
999			_c48032 _d48032